Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology

Thomas R E Barnes; Richard Drake; Carol Paton; Stephen J. Cooper; J.F. William  Deakin; I Nicol Ferrier; Catherine Gregory; Peter Haddad; Oliver Howes; Ian Jones; Eileen M Joyce; Shon Lewis; Anne Lingford-Hughes; James MacCabe; David Cunningham Owens; Maxine Patel; Julia Sinclair; James Stone; Peter Talbot; Rachel Upthegrove; Angelika Wieck; Alison Yung

doi:10.1177/0269881119889296

Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology

Thomas R E Barnes, Richard Drake, Carol Paton, Stephen J. Cooper, J.F. William Deakin, I Nicol Ferrier, Catherine Gregory, Peter Haddad, Oliver Howes, Ian Jones, Eileen M Joyce, Shon Lewis, Anne Lingford-Hughes, James MacCabe, David Cunningham Owens, Maxine Patel, Julia Sinclair, James Stone, Peter Talbot, Rachel UpthegroveAngelika Wieck, Alison Yung

Research output: Contribution to journal › Article › peer-review

161 Downloads (Pure)

Abstract

These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

Original language	English
Pages (from-to)	3-78
Number of pages	76
Journal	Journal of psychopharmacology (Oxford, England)
Volume	34
Issue number	1
Early online date	12 Dec 2019
DOIs	https://doi.org/10.1177/0269881119889296
Publication status	Published - 1 Jan 2020

Keywords

Guideline
psychopharmacology
schizophrenia

Access to Document

10.1177/0269881119889296

0269881119889296Final published version, 534 KB

Cite this

Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C., Haddad, P., Howes, O., Jones, I., Joyce, E. M., Lewis, S., Lingford-Hughes, A., MacCabe, J., Owens, D. C., Patel, M., Sinclair, J., Stone, J., Talbot, P., ... Yung, A. (2020). Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England), 34(1), 3-78. Advance online publication. https://doi.org/10.1177/0269881119889296

@article{5667fb1fcc5b440dbbf1534969f15f87,

title = "Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology",

abstract = "These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.",

keywords = "Guideline, psychopharmacology, schizophrenia",

author = "Barnes, {Thomas R E} and Richard Drake and Carol Paton and Cooper, {Stephen J.} and Deakin, {J.F. William} and Ferrier, {I Nicol} and Catherine Gregory and Peter Haddad and Oliver Howes and Ian Jones and Joyce, {Eileen M} and Shon Lewis and Anne Lingford-Hughes and James MacCabe and Owens, {David Cunningham} and Maxine Patel and Julia Sinclair and James Stone and Peter Talbot and Rachel Upthegrove and Angelika Wieck and Alison Yung",

note = "Funding Information: https://orcid.org/0000-0002-2324-656X Barnes Thomas RE 1 Drake Richard 2 https://orcid.org/0000-0001-7756-1031 Paton Carol 3 Cooper Stephen J 4 Deakin Bill 5 Ferrier I Nicol 6 Gregory Catherine J 7 Haddad Peter M 8 Howes Oliver D 9 Jones Ian 10 Joyce Eileen M 11 Lewis Sh{\^o}n 12 Lingford-Hughes Anne 13 MacCabe James H 14 Owens David Cunningham 15 Patel Maxine X 16 Sinclair Julia MA 17 https://orcid.org/0000-0003-3051-0135 Stone James M 18 Talbot Peter S 19 Upthegrove Rachel 20 Wieck Angelika 21 Yung Alison R 22 1 Emeritus Professor of Clinical Psychiatry, Division of Psychiatry, Imperial College London, and Joint-head of the Prescribing Observatory for Mental Health, Centre for Quality Improvement, Royal College of Psychiatrists, London, UK 2 Clinical Lead for Mental Health in Working Age Adults, Health Innovation Manchester, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 3 Joint-head of the Prescribing Observatory for Mental Health, Centre for Quality Improvement, Royal College of Psychiatrists, London, UK 4 Emeritus Professor of Psychiatry, School of Medicine, Queen{\textquoteright}s University Belfast, Belfast, UK 5 Professor of Psychiatry, Neuroscience & Psychiatry Unit, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 6 Emeritus Professor of Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK 7 Honorary Clinical Research Fellow, University of Manchester and Higher Trainee in Child and Adolescent Psychiatry, Manchester University NHS Foundation Trust, Manchester, UK 8 Honorary Professor of Psychiatry, Division of Psychology and Mental Health, University of Manchester, UK and Senior Consultant Psychiatrist, Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar 9 Professor of Molecular Psychiatry, Imperial College London and Institute of Psychiatry, Psychology and Neuroscience, King{\textquoteright}s College London, London, UK 10 Professor of Psychiatry and Director, National Centre of Mental Health, Cardiff University, Cardiff, UK 11 Professor of Neuropsychiatry, UCL Queen Square Institute of Neurology, London, UK 12 Professor of Adult Psychiatry, Faculty of Biology, Medicine and Health, The University of Manchester, UK, and Mental Health Academic Lead, Health Innovation Manchester, Manchester, UK 13 Professor of Addiction Biology and Honorary Consultant Psychiatrist, Imperial College London and Central North West London NHS Foundation Trust, London, UK 14 Professor of Epidemiology and Therapeutics, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King{\textquoteright}s College London, and Honorary Consultant Psychiatrist, National Psychosis Service, South London and Maudsley NHS Foundation Trust, Beckenham, UK 15 Professor of Clinical Psychiatry, University of Edinburgh. Honorary Consultant Psychiatrist, Royal Edinburgh Hospital, Edinburgh, UK 16 Honorary Clinical Senior Lecturer, King{\textquoteright}s College London, Institute of Psychiatry, Psychology and Neuroscience and Consultant Psychiatrist, Oxleas NHS Foundation Trust, London, UK 17 Professor of Addiction Psychiatry, Faculty of Medicine, University of Southampton, Southampton, UK 18 Clinical Senior Lecturer and Honorary Consultant Psychiatrist, King{\textquoteright}s College London, Institute of Psychiatry, Psychology and Neuroscience and South London and Maudsley NHS Trust, London, UK 19 Senior Lecturer and Honorary Consultant Psychiatrist, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 20 Professor of Psychiatry and Youth Mental Health, University of Birmingham and Consultant Psychiatrist, Birmingham Early Intervention Service, Birmingham Women{\textquoteright}s and Children{\textquoteright}s NHS Foundation Trust, Birmingham, UK 21 Honorary Consultant in Perinatal Psychiatry, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 22 Professor of Psychiatry, University of Manchester, School of Health Sciences, Manchester, UK and Centre for Youth Mental Health, University of Melbourne, Australia, and Honorary Consultant Psychiatrist, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK Thomas R E Barnes, Emeritus Professor of Clinical Psychiatry, Division of Psychiatry, Imperial College London, Du Cane Road, London, W12 0NN, UK. Email: t.r.barnes@imperial.ac.uk 12 2019 0269881119889296 {\textcopyright} The Author(s) 2019 2019 British Association for Psychopharmacology These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement. Guideline schizophrenia psychopharmacology edited-state corrected-proof typesetter ts1 Declaration of Conflicting Interest The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TREB: In the last 3 years, member of scientific advisory boards for Lundbeck, Newron Pharmaceuticals and Gedeon Richter and in receipt of speaker fees from Janssen. R D: No personal interests to declare. CP: No personal interests to declare. SJC: From 2010 to 2018, Clinical Lead for the National Audit of Schizophrenia/National Clinical Audit of Psychosis. No fees, grants or honoraria from pharmaceutical companies accepted during the last 10 years but travel expenses accepted, where necessary, to present NAS/NCAP findings. BD: In the last 3 years, BD has carried out experimental studies in healthy volunteers funded by Autifony, Sunovion and P1vital. He is a paid member of the scientific advisory board of Autifony. INF: No personal interests to declare. CJG: No personal interests to declare. PMH: In the last 3 years, PMH has received fees for lecturing and/or consultancy work (including attending advisory boards) from Janssen, Lundbeck, NewBridge Pharmaceuticals, Otsuka and Sunovion and conference support from Sunovion. ODH: Investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, Autifony, Biogen, Heptares, Jansenn, Lundbeck-Otsuka, Lyden-Delta, Sunovion, and Roche. Neither ODH nor his family have been employed by or have holdings/a financial stake in any pharmaceutical company. IJ: No personal interests to declare. EMJ: No personal interests to declare. SL: In the last 3 years, CDAs with J&J, Otsuka Health Sciences. Founding Director, Affigo CiC. Medical director, Xenzone PLC. ALH : In the last 3 years, ALH has received fees for lecturing and/or consultancy work Lundbeck, Janssen-Cilag, Silence and unpaid consultancy with Opiant, Dobrin, Lightlake, Britannia, GLG. JHM: In the last 3 years, JHM has received travel and accommodation expenses and research funding from Lundbeck. DCO: No personal interests to declare. MXP: In the last 3 years, MXP has been a member of scientific advisory boards for Janssen and Lundbeck and has been PI on studies sponsored by Takeda and Amgen. JMAS: No personal interests to declare. JMS: In the last 3 years, JMS has received fees for consultancy work from Janssen Pharmaceutica and has been PI or sub-investigator on studies sponsored by Takeda, Janssen, Lundbeck and Allergan Plc. PST: Between 2015 and 2018 PST received consultancy fees as an Advisory Board member for Galen Limited; Sunovion Pharmaceuticals Europe Ltd; myTomorrows; and LivaNova UK Ltd. Since 2018 PTS has been sub-investigator on a clinical drug trial sponsored by COMPASS Pathways Ltd, UK. RU: In the last 3 years, fees received for lecturing from Lundbeck. AW: No personal interests to declare. ARY : In the last 3 years, fees received for lecturing and/or consultancy work and conference support from Janssen and Boehringer-Ingelheim. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. ORCID iDs Thomas R E Barnes https://orcid.org/0000-0002-2324-656X Carol Paton https://orcid.org/0000-0001-7756-1031 James M Stone https://orcid.org/0000-0003-3051-0135 Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2020",

month = jan,

day = "1",

doi = "10.1177/0269881119889296",

language = "English",

volume = "34",

pages = "3--78",

journal = "Journal of psychopharmacology (Oxford, England)",

issn = "0269-8811",

publisher = "Sage Publications Ltd",

number = "1",

}

Barnes, TRE, Drake, R, Paton, C, Cooper, SJ, Deakin, JFW, Ferrier, IN, Gregory, C, Haddad, P, Howes, O, Jones, I, Joyce, EM, Lewis, S, Lingford-Hughes, A, MacCabe, J, Owens, DC, Patel, M, Sinclair, J, Stone, J, Talbot, P, Upthegrove, R, Wieck, A & Yung, A 2020, 'Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology', Journal of psychopharmacology (Oxford, England), vol. 34, no. 1, pp. 3-78. https://doi.org/10.1177/0269881119889296

Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. / Barnes, Thomas R E; Drake, Richard; Paton, Carol et al.
In: Journal of psychopharmacology (Oxford, England), Vol. 34, No. 1, 01.01.2020, p. 3-78.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology

AU - Barnes, Thomas R E

AU - Drake, Richard

AU - Paton, Carol

AU - Cooper, Stephen J.

AU - Deakin, J.F. William

AU - Ferrier, I Nicol

AU - Gregory, Catherine

AU - Haddad, Peter

AU - Howes, Oliver

AU - Jones, Ian

AU - Joyce, Eileen M

AU - Lewis, Shon

AU - Lingford-Hughes, Anne

AU - MacCabe, James

AU - Owens, David Cunningham

AU - Patel, Maxine

AU - Sinclair, Julia

AU - Stone, James

AU - Talbot, Peter

AU - Upthegrove, Rachel

AU - Wieck, Angelika

AU - Yung, Alison

N1 - Funding Information: https://orcid.org/0000-0002-2324-656X Barnes Thomas RE 1 Drake Richard 2 https://orcid.org/0000-0001-7756-1031 Paton Carol 3 Cooper Stephen J 4 Deakin Bill 5 Ferrier I Nicol 6 Gregory Catherine J 7 Haddad Peter M 8 Howes Oliver D 9 Jones Ian 10 Joyce Eileen M 11 Lewis Shôn 12 Lingford-Hughes Anne 13 MacCabe James H 14 Owens David Cunningham 15 Patel Maxine X 16 Sinclair Julia MA 17 https://orcid.org/0000-0003-3051-0135 Stone James M 18 Talbot Peter S 19 Upthegrove Rachel 20 Wieck Angelika 21 Yung Alison R 22 1 Emeritus Professor of Clinical Psychiatry, Division of Psychiatry, Imperial College London, and Joint-head of the Prescribing Observatory for Mental Health, Centre for Quality Improvement, Royal College of Psychiatrists, London, UK 2 Clinical Lead for Mental Health in Working Age Adults, Health Innovation Manchester, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 3 Joint-head of the Prescribing Observatory for Mental Health, Centre for Quality Improvement, Royal College of Psychiatrists, London, UK 4 Emeritus Professor of Psychiatry, School of Medicine, Queen’s University Belfast, Belfast, UK 5 Professor of Psychiatry, Neuroscience & Psychiatry Unit, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 6 Emeritus Professor of Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK 7 Honorary Clinical Research Fellow, University of Manchester and Higher Trainee in Child and Adolescent Psychiatry, Manchester University NHS Foundation Trust, Manchester, UK 8 Honorary Professor of Psychiatry, Division of Psychology and Mental Health, University of Manchester, UK and Senior Consultant Psychiatrist, Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar 9 Professor of Molecular Psychiatry, Imperial College London and Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK 10 Professor of Psychiatry and Director, National Centre of Mental Health, Cardiff University, Cardiff, UK 11 Professor of Neuropsychiatry, UCL Queen Square Institute of Neurology, London, UK 12 Professor of Adult Psychiatry, Faculty of Biology, Medicine and Health, The University of Manchester, UK, and Mental Health Academic Lead, Health Innovation Manchester, Manchester, UK 13 Professor of Addiction Biology and Honorary Consultant Psychiatrist, Imperial College London and Central North West London NHS Foundation Trust, London, UK 14 Professor of Epidemiology and Therapeutics, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, and Honorary Consultant Psychiatrist, National Psychosis Service, South London and Maudsley NHS Foundation Trust, Beckenham, UK 15 Professor of Clinical Psychiatry, University of Edinburgh. Honorary Consultant Psychiatrist, Royal Edinburgh Hospital, Edinburgh, UK 16 Honorary Clinical Senior Lecturer, King’s College London, Institute of Psychiatry, Psychology and Neuroscience and Consultant Psychiatrist, Oxleas NHS Foundation Trust, London, UK 17 Professor of Addiction Psychiatry, Faculty of Medicine, University of Southampton, Southampton, UK 18 Clinical Senior Lecturer and Honorary Consultant Psychiatrist, King’s College London, Institute of Psychiatry, Psychology and Neuroscience and South London and Maudsley NHS Trust, London, UK 19 Senior Lecturer and Honorary Consultant Psychiatrist, University of Manchester and Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 20 Professor of Psychiatry and Youth Mental Health, University of Birmingham and Consultant Psychiatrist, Birmingham Early Intervention Service, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK 21 Honorary Consultant in Perinatal Psychiatry, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK 22 Professor of Psychiatry, University of Manchester, School of Health Sciences, Manchester, UK and Centre for Youth Mental Health, University of Melbourne, Australia, and Honorary Consultant Psychiatrist, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK Thomas R E Barnes, Emeritus Professor of Clinical Psychiatry, Division of Psychiatry, Imperial College London, Du Cane Road, London, W12 0NN, UK. Email: t.r.barnes@imperial.ac.uk 12 2019 0269881119889296 © The Author(s) 2019 2019 British Association for Psychopharmacology These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement. Guideline schizophrenia psychopharmacology edited-state corrected-proof typesetter ts1 Declaration of Conflicting Interest The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TREB: In the last 3 years, member of scientific advisory boards for Lundbeck, Newron Pharmaceuticals and Gedeon Richter and in receipt of speaker fees from Janssen. R D: No personal interests to declare. CP: No personal interests to declare. SJC: From 2010 to 2018, Clinical Lead for the National Audit of Schizophrenia/National Clinical Audit of Psychosis. No fees, grants or honoraria from pharmaceutical companies accepted during the last 10 years but travel expenses accepted, where necessary, to present NAS/NCAP findings. BD: In the last 3 years, BD has carried out experimental studies in healthy volunteers funded by Autifony, Sunovion and P1vital. He is a paid member of the scientific advisory board of Autifony. INF: No personal interests to declare. CJG: No personal interests to declare. PMH: In the last 3 years, PMH has received fees for lecturing and/or consultancy work (including attending advisory boards) from Janssen, Lundbeck, NewBridge Pharmaceuticals, Otsuka and Sunovion and conference support from Sunovion. ODH: Investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, Autifony, Biogen, Heptares, Jansenn, Lundbeck-Otsuka, Lyden-Delta, Sunovion, and Roche. Neither ODH nor his family have been employed by or have holdings/a financial stake in any pharmaceutical company. IJ: No personal interests to declare. EMJ: No personal interests to declare. SL: In the last 3 years, CDAs with J&J, Otsuka Health Sciences. Founding Director, Affigo CiC. Medical director, Xenzone PLC. ALH : In the last 3 years, ALH has received fees for lecturing and/or consultancy work Lundbeck, Janssen-Cilag, Silence and unpaid consultancy with Opiant, Dobrin, Lightlake, Britannia, GLG. JHM: In the last 3 years, JHM has received travel and accommodation expenses and research funding from Lundbeck. DCO: No personal interests to declare. MXP: In the last 3 years, MXP has been a member of scientific advisory boards for Janssen and Lundbeck and has been PI on studies sponsored by Takeda and Amgen. JMAS: No personal interests to declare. JMS: In the last 3 years, JMS has received fees for consultancy work from Janssen Pharmaceutica and has been PI or sub-investigator on studies sponsored by Takeda, Janssen, Lundbeck and Allergan Plc. PST: Between 2015 and 2018 PST received consultancy fees as an Advisory Board member for Galen Limited; Sunovion Pharmaceuticals Europe Ltd; myTomorrows; and LivaNova UK Ltd. Since 2018 PTS has been sub-investigator on a clinical drug trial sponsored by COMPASS Pathways Ltd, UK. RU: In the last 3 years, fees received for lecturing from Lundbeck. AW: No personal interests to declare. ARY : In the last 3 years, fees received for lecturing and/or consultancy work and conference support from Janssen and Boehringer-Ingelheim. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. ORCID iDs Thomas R E Barnes https://orcid.org/0000-0002-2324-656X Carol Paton https://orcid.org/0000-0001-7756-1031 James M Stone https://orcid.org/0000-0003-3051-0135 Publisher Copyright: © The Author(s) 2019.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

AB - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

KW - Guideline

KW - psychopharmacology

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85077370077&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/c7532530-07b5-3d3b-9b94-9c3e3ac7cde8/

U2 - 10.1177/0269881119889296

DO - 10.1177/0269881119889296

M3 - Article

SN - 0269-8811

VL - 34

SP - 3

EP - 78

JO - Journal of psychopharmacology (Oxford, England)

JF - Journal of psychopharmacology (Oxford, England)

IS - 1

ER -

Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this